AstraZeneca inaugurates $224M Russian plant; Flu vax makers ship record number of shots in U.S.;

@FiercePharma: Japanese drugmakers Eisai, Ajinomoto team up on gastrointestinal diseases. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Regeneron more than doubles investment in plant in Ireland, adding 200 more workers. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI: Merck KGaA exits 'sea of sameness' with futuristic rebrand. More | Follow @CarlyHFierce

> AstraZeneca ($AZN) opened a new $224 million plant in Russia, with plans to produce more than half its drugs for the Russian market there by 2017. Report

> Manufacturers are distributing a record number of flu vaccines this year, with up to 179 million doses shipping in the U.S. Report

> Controversy over the pharma-related provisions of the Trans-Pacific Partnership (TPP) could derail the treaty's approval, experts say. Report

> Pharma companies in India--both domestic and multinational--are teaming up to push for ethical marketing practices and to clean up their image. Report

Medical Device News

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@VarunSaxena2: Fierce 15 co. Shockwave Medical aims to deploy energy-delivering balloons in the peripheral and coronary arteries. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: Lightpoint Medical nabs EU approval for cancer molecular imaging device. Article | Follow @EmilyWFierce

> Stryker scores point in patent battle with Zimmer. More

> Philips spins Axsun back out of Volcano, sells it to venture firm. Story

Biotech News

@FierceBiotech: FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval. Story | Follow @FierceBiotech

@JohnCFierce: Anthony Philippakis at The Broad will be on my JP Morgan Big Data panel. Any other recommendations for Drug Development and Big Data: 2025? | Follow @JohnCFierce

> Actelion says it doesn't need big buyouts as billion-dollar rumors simmer. Report

> Genentech co-signs Nimbus' computer-aided R&D with an oncology pact. Article

> Big science: Upstart Gritstone bags $102M to go after a new immuno-oncology target. More

> Bluebird shares dented after gene therapy patient experiences a setback. Story

Drug Delivery News

> Computer models demonstrate stronger liposomal shells for drug delivery. More

> Researchers deploy malarial protein as targeting agent for anticancer drugs. Report

> Ear drug delivery to get a boost from launch of hearing loss therapeutics company Decibel. Item

> Alnylam reveals molecule to reverse effect of its RNAi therapies. Story

> Novo to expand use of Emisphere's oral delivery platform in deal potentially worth $80M+. Article

Pharma Manufacturing News

> FDA cites Cipla India plant after U.S. recall of asthma drug. News

> Recipharm shelling out $105M for Indian sterile injectables CMO. Report

> Hovione adding a formulation plant in Portugal. More

> TxCell, whose plant was closed for mold issues, intends to use CMOs exclusively. Story

> Regeneron doubles down on plant project in Ireland. Article

Pharma Asia News

> Indian drug manufacturers face higher costs with bar-code requirement. Report

> NY-based Athenex has big China manufacturing plans with name change to boot. Story

> Japan's Daiichi Sankyo to cut as many as 1,200 U.S. jobs in reorganization. Item

> Vietnam's Vinamilk on the block--will Abbott bite? More

> HK-based Chi-Med looks to tap funds in Nasdaq listing with China focus. Article

And Finally... Regulating dopamine levels in the brain can reduce alcohol cravings, a study found. Report

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.